Association Between Number of Vasopressors and Mortality in COVID-19 Patients

Authors

Michael Sunnaa
Mina Kerolos
Max Ruge, Thomas Jefferson UniversityFollow
Ahmad Gill
Jeanne M. Du-Fay-de-Lavallaz
Perry Robin
Joanne Michelle Dumlao Gomez
Kim Williams
Anupama Rao
Annabelle Santos Volgman
Karolina Marinescu
Tisha Marie Suboc

Document Type

Article

Publication Date

9-16-2023

Comments

This article is the author's final published version in the American Heart Journal Plus: Cardiology Research and Practice, Volume 34, October 2023, Article number 100324.

The published version is available at https://doi.org/10.1016/j.ahjo.2023.100324. Copyright © 2023 The Author(s). Published by Elsevier Inc.

Abstract

Study objective

Study the clinical outcomes associated with the number of concomitant vasopressors used in critically ill COVID-19 patients.

Design

A single-center retrospective cohort study was conducted on patients admitted with COVID-19 to the intensive care unit (ICU) between March and October 2020.

Setting

Rush University Medical Center, United States.

Participants

Adult patients at least 18 years old with COVID-19 with continuous infusion of any vasopressors were included.

Main outcome measures

60-day mortality in COVID-19 patients by the number of concurrent vasopressors received.

Results

A total of 637 patients met our inclusion criteria, of whom 338 (53.1 %) required the support of at least one vasopressor. When compared to patients with no vasopressor requirement, those who required 1 vasopressor (V1) (adjusted odds ratio [aOR] 3.27, 95 % confidence interval (CI) 1.86–5.79, p < 0.01) (n = 137), 2 vasopressors (V2) (aOR 4.71, 95 % CI 2.54–8.77, p < 0.01) (n = 86), 3 vasopressors (V3) (aOR 26.2, 95 % CI 13.35–53.74 p < 0.01) (n = 74), and 4 or 5 vasopressors(V4–5) (aOR 106.38, 95 % CI 39.17–349.93, p < 0.01) (n = 41) were at increased risk of 60-day mortality. In-hospital mortality for patients who received no vasopressors was 6.7 %, 22.6 % for V1, 27.9 % for V2, 62.2 % for V3, and 78 % for V4-V5.

Conclusion

Critically ill patients with COVID-19 requiring vasopressors were associated with significantly higher 60-day mortality.

Recommended Citation

Sunnaa, Michael; Kerolos, Mina; Ruge, Max; Gill, Ahmad; Du-Fay-de-Lavallaz, Jeanne M.; Robin, Perry; Gomez, Joanne Michelle Dumlao; Williams, Kim; Rao, Anupama; Volgman, Annabelle Santos; Marinescu, Karolina; and Suboc, Tisha Marie, "Association Between Number of Vasopressors and Mortality in COVID-19 Patients" (2023). COVID-19 Papers, Posters, and Presentations. Paper 8.
https://jdc.jefferson.edu/covid-19/8

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English